It was a short but busy week for FDA, marked by the first approval of a new molecular entity in 2017: Synergy Pharmaceuticals Inc.'s chronic idiopathic constipation therapy Trulance.
FDA also approved a new hematologic cancer indication for Johnson & Johnson and AbbVie Inc.'s Imbruvica, a new abuse-deterrent opioid formulation from Teva Pharmaceutical Industries Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?